-
公开(公告)号:US11471406B2
公开(公告)日:2022-10-18
申请号:US17063644
申请日:2020-10-05
Applicant: INTELGENX CORP.
Inventor: Nadine Paiement , Rodolphe Obeid , Justin Conway , Billal Tir
IPC: A61K9/00 , A61K47/38 , A61K31/4985
Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm.
-
公开(公告)号:US20170258710A1
公开(公告)日:2017-09-14
申请号:US15067309
申请日:2016-03-11
Applicant: Intelgenx Corp.
Inventor: Justin Conway , Rodolphe Obeid , Nadine Paiement , Horst Zerbe
Abstract: An oral film product in which a pharmaceutically active agent is stabilized in its partially-ionized form to better facilitate oral transmucosal delivery is provided. The film includes a bioadhesive layer including a pharmaceutically active agent having a logarithmic acid dissociation constant that is less than 4.5 and which is complexed with a cationic polymer.
-
公开(公告)号:US12156937B2
公开(公告)日:2024-12-03
申请号:US17952300
申请日:2022-09-25
Applicant: INTELGENX CORP.
Inventor: Nadine Paiement , Rodolphe Obeid , Justin Conway , Billal Tir
IPC: A61K9/00 , A61K31/4985 , A61K47/38
Abstract: An oral film dosage form includes a high viscosity polymer in an amount of from 1% to 5% by dry weight to reduce, modulate and/or control Cmax of an active agent. The high viscosity polymer has a viscosity of from 100 cps to 500 cps as determined at 2% concentration in water by weight at 25° C. using a Brookfield LVF viscometer with spindle no. 2 at 60 rpm.
-
公开(公告)号:US11602504B2
公开(公告)日:2023-03-14
申请号:US16383813
申请日:2019-04-15
Applicant: Intelgenx Corp.
Inventor: Carolin Madwar , Nadine Paiement , Rodolphe Obeid , Justin Conway , Erick Gonzalez-Labrada
IPC: A61K9/70 , A61K31/352 , A61K31/47 , A61K9/00
Abstract: Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive log P. The method involves dispersing the lipophilic active(s) in a carrier oil and uniformly distributing them as emulsified oil droplets into a polymer matrix. The methods reported here produce oral films containing a stable emulsion with up to 40% oil phase. The oil phase consists of the carrier oil and lipophilic active(s). This offers the possibility to enhance the amount of lipophilic actives to be included in the film formulation while preserving the film characteristics. The resulting oral films offer a standardized dosage form for lipophilic actives as well as easier and more convenient administration, transportation, handling, and storage.
-
-
-